Nasdaq
华尔街日报Global Growth Companies With Strong Insider Ownership
Amidst a backdrop of fluctuating global markets, where U.S. indices have hit all-time highs due to the Federal Reserve’s interest rate cuts and European growth prospects remain cautiously optimistic, investors are increasingly focusing on companies with robust fundamentals. In particular, growth companies with high insider ownership can offer potential advantages in such an environment, as they may align management's interests with those of shareholders and demonstrate confidence in the company's long-term prospects.
Top 10 Growth Companies With High Insider Ownership Globally
| Name | Insider Ownership | Earnings Growth |
| Streamax Technology (SZSE:002970) | 32.5% | 33.1% |
| Rasan Information Technology (SASE:8313) | 31.1% | 21% |
| Novoray (SHSE:688300) | 23.6% | 31.4% |
| Loadstar Capital K.K (TSE:3482) | 31% | 23.6% |
| Laopu Gold (SEHK:6181) | 34.8% | 34.3% |
| KebNi (OM:KEBNI B) | 36.3% | 61.2% |
| J&V Energy Technology (TWSE:6869) | 17.5% | 31.6% |
| Gold Circuit Electronics (TWSE:2368) | 31.4% | 37.2% |
| Fulin Precision (SZSE:300432) | 11.6% | 55.2% |
| CD Projekt (WSE:CDR) | 29.7% | 51.8% |
Here we highlight a subset of our preferred stocks from the screener.
Aimed Bio (KOSDAQ:A0009K0)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Aimed Bio Inc. develops therapeutic solutions for brain diseases, including neuro-oncological and degenerative conditions, with a market cap of ₩4.64 trillion.
Operations: The company's revenue is derived from researching, developing, producing, and selling antibody-based therapeutics, amounting to ₩20.71 billion.
Insider Ownership: 34.5%
Revenue Growth Forecast: 35.2% p.a.
Aimed Bio recently completed a KRW 70.73 billion IPO, highlighting its growth potential. The company entered a significant collaboration with Boehringer Ingelheim to develop an antibody-drug conjugate therapy targeting cancer, potentially bringing in up to $991 million. Despite highly illiquid shares, Aimed Bio's revenue is forecasted to grow at 35.2% annually, surpassing market expectations and positioning it for profitability within three years without substantial insider trading activity recently noted.
- Click to explore a detailed breakdown of our findings in Aimed Bio's earnings growth report.
- According our valuation report, there's an indication that Aimed Bio's share price might be on the expensive side.
SBT Ultrasonic Technology (SHSE:688392)
Simply Wall St Growth Rating: ★★★★★☆
Overview: SBT Ultrasonic Technology Co., Ltd. is involved in the research, development, design, production, and sale of ultrasonic equipment globally and has a market cap of CN¥12.13 billion.
Operations: The company's revenue primarily comes from its Machinery & Industrial Equipment segment, totaling CN¥696.91 million.
Insider Ownership: 21.2%
Revenue Growth Forecast: 32.5% p.a.
SBT Ultrasonic Technology's earnings surged with a net income of CNY 94.03 million for the first nine months of 2025, up from CNY 20.45 million the previous year. Revenue is forecast to grow at an impressive 32.5% annually, outpacing market expectations, while earnings are projected to increase by 37.1%. Despite high non-cash earnings and share price volatility, SBT's growth trajectory remains robust without recent insider trading activity influencing its performance outlook.
- Delve into the full analysis future growth report here for a deeper understanding of SBT Ultrasonic Technology.
- In light of our recent valuation report, it seems possible that SBT Ultrasonic Technology is trading beyond its estimated value.
Fujian Wanchen Biotechnology GroupLtd (SZSE:300972)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Fujian Wanchen Biotechnology Group Ltd (SZSE:300972) is involved in the research, development, cultivation, production, and sale of edible fungi both in China and internationally, with a market cap of CN¥33.72 billion.
Operations: Fujian Wanchen Biotechnology Group Ltd generates revenue through its activities in the research, development, cultivation, production, and sale of edible fungi across domestic and international markets.
Insider Ownership: 22.9%
Revenue Growth Forecast: 16% p.a.
Fujian Wanchen Biotechnology Group Ltd. has demonstrated substantial growth, with net income rising from CNY 84.07 million to CNY 854.98 million over the past year, and is trading at a significant discount to its estimated fair value. The company's earnings are projected to grow at an impressive rate of 31.38% annually, surpassing the broader Chinese market's growth expectations. Recent inclusion in major stock indices highlights its growing prominence despite no recent insider trading activity affecting its outlook.
- Click here to discover the nuances of Fujian Wanchen Biotechnology GroupLtd with our detailed analytical future growth report.
- Our comprehensive valuation report raises the possibility that Fujian Wanchen Biotechnology GroupLtd is priced lower than what may be justified by its financials.
Next Steps
- Access the full spectrum of 866 Fast Growing Global Companies With High Insider Ownership by clicking on this link.
- Ready For A Different Approach? Uncover the next big thing with financially sound penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com